South Korean Pharmaceutical Industry to Achieve $24.3 Billion Value by 2020, Despite Large Focus on Generic Drugs, says GlobalData
South Korean pharmaceutical industry value to grow from $19.3 billion in 2013 to $24.3 billion by 2020
Thanks to a high level of access to healthcare insurance and reimbursement, coupled with increasing demand for healthcare services from an expanding elderly population, the South Korean pharmaceutical market is expected to climb in value from $19.3 billion in 2013 to $24.3 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 3.9%, says research and consulting firm GlobalData.
According to the company’s latest report*, the South Korean pharmaceutical industry is also expected to be influenced by various government initiatives over the coming years, such as the Korean Small Business Innovation Research program. These projects are aimed at encouraging Research and Development activities and sustaining growth in the pharmaceutical sector.
Joshua Owide, Director of Healthcare Industry Dynamics at GlobalData, says: “In order to boost private investment, the South Korean government chose to provide 44 pharma companies with special benefits, such as tax reduction and exemption, funding for research projects, and a delay in drug price cuts.
“Additionally, since signing the Free Trade Agreement with the US in 2007, South Korea has lowered its import tariffs, enhanced its regulatory transparency, and attracted investment from multinational pharmaceutical companies.”
However, South Korea is maintaining its focus on generics as a cost-containment measure to slow the rise of its healthcare expenditure, which could hurt branded-drugs profits. In fact, the country’s generic market value has increased from $3.5 billion in 2008 to an estimated $4.9 billion in 2013, at a CAGR of 7%, according to GlobalData.
“Since many drugs are set to lose their patents within the next five years, South Korea’s generics industry is only going to expand further during the coming decade,” Owide concludes.
*CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - South Korea
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
